

SECRET

Under Sec. 1.56, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and (1) It establishes, by itself or in combination with other information, a prima facie

Inventor: Guido Krupp
Serial No. 09/937,519
Filed: September 25, 2001
Page 2

case of unpatentability of a claim; or (2) It refutes, or is inconsistent with, a position the applicant takes in: (a) Opposing an argument of unpatentability relied on by the U.S. Patent and Trademark Office, or (b) Asserting an argument of patentability.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

My citizenship, residence and mailing address are correctly stated below my name:

Full name of inventor: Guido Krupp

Citizenship: Germany

Residence: Kiel, Germany

DET
Rosenstr. 3, D-24622 Gnatz
Mailing Address: Wannseebogen 30A, D-24111 Kiel, Germany

11.12.2001

G. Krupp

Signature: *G. Krupp*

Date: 11.12.2001

POWER OF ATTORNEY

Assignee **Artus Gesellschaft für molekularbiologische
Diagnostik und Entwicklung mbH**

is the owner of the entire right, title and interest of the following U.S. patent application identified below and any subsequently filed divisional, continuation, continuation-in-part or reissue applications claiming priority thereto.

Title: **DETECTION OF NUCLEIC ACID AMPLIFIED PRODUCTS**

International Patent Application No. **PCT/EP99/07127**

International filing date: **September 27, 1999**

Claiming priority to prior **German** application

Serial No. **199 15 141.5**

Filing (priority) date: **March 26, 1999**

Entry into U.S. national stage as Serial No. **09/937,519**

U.S. National Stage entry date: **September 25, 2001**

As amended with English PCT claims filed therewith

U.S. Applicant / Inventor: **Guido Krupp**

Campbell & Flores Attorney Docket No. **P-UX 4977 (P 58130)**

The Assignee hereby appoints the following attorneys to prosecute these applications and to transact all related business in the United States Patent and Trademark Office:

10 CATHRYN CAMPBELL, Registration No. 31,815;
DAVID A. GAY, Registration No. 39,200;
CALVIN A. FAN, Registration No. 38,444;
ANDREA L. GASHLER, Registration No. 41,029;
JAMES J. WONG, Registration No. 34,949;
DEBORAH L. CADENA, Registration No. 44,048;
MELANIE K. WEBSTER, Registration No. 45,201;
ASTRID R. SPAIN, Registration No. 47,956;
MARGARET M. PARR, Registration No. 48,111; and
KIMBERLY J. PRIOR, Registration No. 41,483.

Inventor: Guido Krupp
Serial No. 09/937,519
Filed: September 25, 2001
Page 2

Please direct all telephone calls to Cathryn Campbell at
(858) 535-9001 and address all correspondence to

CATHRYN CAMPBELL
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
USPTO CUSTOMER NO. 23601

The undersigned is empowered to sign this statement on behalf of
the assignee.

Date: 11.12.2001

Signature: [Handwritten Signature]

Name: Dr. U. Spengler

Title: CEO

Artus Gesellschaft für
molekularbiologische
Diagnostik und Entwicklung mbH

Gerstäckerstrasse 9
D-20459 Hamburg, Germany

205060-6752660